Amneal Is Targeting 70% Of Untapped Biologics In The ‘Golden Era’ Of Biosimilars

As The Firm Prepares For First Generic Rivals For Its Innovative Parkinson’s Drug Rytary

While Amneal cannot wait to jump into unexplored biologics space, it wants to channel its GLP-1 power into the Metsera partnership and service big pharma, and less so on its own generics.

A vault full of gold bars
(Shutterstock)

“It is our cup of tea,” is how Amneal’s co-CEO Chirag Patel described the firm’s passion for biosimilars at the recent J.P. Morgan Healthcare Conference.

The firm has previously acknowledged the integration of biosimilars as a key business development priority in 2025. Patel shared...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Business